{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T16:37:07Z","timestamp":1778431027285,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100005117","name":"Birjand University of Medical Sciences","doi-asserted-by":"publisher","award":["IR.BUMS.REC.1403.027."],"award-info":[{"award-number":["IR.BUMS.REC.1403.027."]}],"id":[{"id":"10.13039\/501100005117","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03147-9","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T06:01:56Z","timestamp":1763964116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exosome-mediated modulation of bortezomib cytotoxicity in multiple myeloma cells: involvement of redox balance and cell cycle arrest through ketotifen treatment"],"prefix":"10.1007","volume":"43","author":[{"given":"Nazgol","family":"Nourafshan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gholamreza Anani","family":"Sarab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Behzad","family":"Mesbahzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3087-705X","authenticated-orcid":false,"given":"Mahtab","family":"Sayadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"issue":"9","key":"3147_CR1","doi-asserted-by":"publisher","first-page":"e1406","DOI":"10.1634\/theoncologist.2020-0141","volume":"25","author":"H Ludwig","year":"2020","unstructured":"Ludwig H, Novis Durie S, Meckl A, Hinke A, Durie B. Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment. Oncologist. 2020;25(9):e1406-13.","journal-title":"Oncologist"},{"key":"3147_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ph16030415","author":"WO Elbezanti","year":"2023","unstructured":"Elbezanti WO, Challagundla KB, Jonnalagadda SC, Budak-Alpdogan T, Pandey MK. Past, present, and a glance into the future of multiple myeloma treatment. Pharmaceuticals (Basel). 2023. https:\/\/doi.org\/10.3390\/ph16030415.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"3147_CR3","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.3747\/co.21.1798","volume":"21","author":"TC Kouroukis","year":"2014","unstructured":"Kouroukis TC, Baldassarre FG, Haynes AE, Imrie K, Reece DE, Cheung MC. Bortezomib in multiple myeloma: systematic review and clinical considerations. Curr Oncol. 2014;21(4):e573\u2013603.","journal-title":"Curr Oncol"},{"key":"3147_CR4","first-page":"146","volume":"22","author":"M Alwahsh","year":"2023","unstructured":"Alwahsh M, Farhat J, Talhouni S, Hamadneh L, Hergenr\u00f6der R. Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications. EXCLI J. 2023;22:146\u201368.","journal-title":"EXCLI J"},{"key":"3147_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ph16010111","author":"G Kozalak","year":"2023","unstructured":"Kozalak G, B\u00fct\u00fcn \u0130, Toyran E, Ko\u015far A. Review on bortezomib resistance in multiple myeloma and potential role of emerging technologies. Pharmaceuticals (Basel). 2023. https:\/\/doi.org\/10.3390\/ph16010111.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"3147_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.bbcan.2018.07.003","volume":"1870","author":"N Mc Namee","year":"2018","unstructured":"Mc Namee N, O\u2019Driscoll L. Extracellular vesicles and anti-cancer drug resistance. Biochim Et Biophys Acta (BBA)-Reviews Cancer. 2018;1870(2):123\u201336.","journal-title":"Biochim Et Biophys Acta (BBA)-Reviews Cancer"},{"issue":"1","key":"3147_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19339-5","volume":"8","author":"JC Santos","year":"2018","unstructured":"Santos JC, Lima NdS, Sarian LO, Matheu A, Ribeiro ML, Derchain SFM. Exosome-mediated breast cancer chemoresistance via miR-155 transfer. Sci Rep. 2018;8(1):829.","journal-title":"Sci Rep"},{"issue":"2","key":"3147_CR8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3390\/cancers11020136","volume":"11","author":"CP O\u2019Neill","year":"2019","unstructured":"O\u2019Neill CP, Gilligan KE, Dwyer RM. Role of extracellular vesicles (EVs) in cell stress response and resistance to cancer therapy. Cancers. 2019;11(2):136.","journal-title":"Cancers"},{"key":"3147_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cells10112865","author":"A Allegra","year":"2021","unstructured":"Allegra A, Di Gioacchino M, Tonacci A, Petrarca C, Musolino C, Gangemi S. Multiple myeloma cell-derived exosomes: implications on tumorigenesis, diagnosis, prognosis and therapeutic strategies. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10112865.","journal-title":"Cells"},{"key":"3147_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2024.109994","volume":"756","author":"A Ramezani","year":"2024","unstructured":"Ramezani A, Tafazoli A, Salimi F, Ghavami M, Arjmandi H, Khalesi B, et al. Current knowledge on therapeutic, diagnostic, and prognostics applications of exosomes in multiple myeloma: opportunities and challenges. Arch Biochem Biophys. 2024;756:109994.","journal-title":"Arch Biochem Biophys"},{"issue":"5","key":"3147_CR11","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/j.gendis.2022.03.021","volume":"10","author":"M Xu","year":"2023","unstructured":"Xu M, Ji J, Jin D, Wu Y, Wu T, Lin R, et al. The biogenesis and secretion of exosomes and multivesicular bodies (MVBs): Intercellular shuttles and implications in human diseases. Genes & Diseases. 2023;10(5):1894\u2013907.","journal-title":"Genes & Diseases"},{"issue":"8","key":"3147_CR12","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1083\/jcb.201710132","volume":"217","author":"SW Messenger","year":"2018","unstructured":"Messenger SW, Woo SS, Sun Z, Martin TFJ. A Ca2+-stimulated exosome release pathway in cancer cells is regulated by Munc13-4. J Cell Biol. 2018;217(8):2877\u201390.","journal-title":"J Cell Biol"},{"issue":"1","key":"3147_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.tcb.2013.10.009","volume":"24","author":"C Bissig","year":"2014","unstructured":"Bissig C, Gruenberg J. ALIX and the multivesicular endosome: ALIX in wonderland. Trends Cell Biol. 2014;24(1):19\u201325.","journal-title":"Trends Cell Biol"},{"key":"3147_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.matbio.2017.09.001","volume":"65","author":"SK Bandari","year":"2018","unstructured":"Bandari SK, Purushothaman A, Ramani VC, Brinkley GJ, Chandrashekar DS, Varambally S, et al. Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. Matrix Biol. 2018;65:104\u201318.","journal-title":"Matrix Biol"},{"issue":"4","key":"3147_CR15","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/cas.14351","volume":"111","author":"M Ge","year":"2020","unstructured":"Ge M, Qiao Z, Kong Y, Lu H, Liu H. Exosomes mediate intercellular transfer of non\u2013autonomous tolerance to proteasome inhibitors in mixed-lineage leukemia. Cancer Sci. 2020;111(4):1279\u201390.","journal-title":"Cancer Sci"},{"issue":"5\u20136","key":"3147_CR16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/BF00374562","volume":"428","author":"D Franzius","year":"1994","unstructured":"Franzius D, Hoth M, Penner R. Non-specific effects of calcium entry antagonists in mast cells. Pflugers Arch. 1994;428(5\u20136):433\u20138.","journal-title":"Pflugers Arch"},{"issue":"22","key":"3147_CR17","doi-asserted-by":"publisher","first-page":"20083","DOI":"10.1074\/jbc.M301642200","volume":"278","author":"A Savina","year":"2003","unstructured":"Savina A, Furl\u00e1n M, Vidal M, Colombo MI. Exosome release is regulated by a calcium-dependent mechanism in K562 cells. J Biol Chem. 2003;278(22):20083\u201390.","journal-title":"J Biol Chem"},{"issue":"1","key":"3147_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/15384047.2017.1394544","volume":"19","author":"FM Khan","year":"2018","unstructured":"Khan FM, Saleh E, Alawadhi H, Harati R, Zimmermann WH, El-Awady R. Inhibition of exosome release by ketotifen enhances sensitivity of cancer cells to doxorubicin. Cancer Biol Ther. 2018;19(1):25\u201333.","journal-title":"Cancer Biol Ther"},{"issue":"11","key":"3147_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0139-7","volume":"8","author":"S Faict","year":"2018","unstructured":"Faict S, Muller J, De Veirman K, De Bruyne E, Maes K, Vrancken L, et al. Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts. Blood Cancer J. 2018;8(11):105.","journal-title":"Blood Cancer J"},{"issue":"4","key":"3147_CR20","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1182\/blood-2014-03-562439","volume":"124","author":"J Wang","year":"2014","unstructured":"Wang J, Hendrix A, Hernot S, Lemaire M, De Bruyne E, Van Valckenborgh E, et al. Bone marrow stromal cell\u2013derived exosomes as communicators in drug resistance in multiple myeloma cells. Blood. 2014;124(4):555\u201366.","journal-title":"Blood"},{"issue":"5","key":"3147_CR21","doi-asserted-by":"publisher","first-page":"685","DOI":"10.3390\/biom15050685","volume":"15","author":"G Liu","year":"2025","unstructured":"Liu G, Liu J, Li S, Zhang Y, Ren H. Exosome-mediated chemoresistance in cancers: mechanisms, therapeutic implications, and future directions. Biomolecules. 2025;15(5):685.","journal-title":"Biomolecules"},{"key":"3147_CR22","doi-asserted-by":"crossref","unstructured":"Chen T, Moscvin M, Bianchi G. Exosomes in the pathogenesis and treatment of multiple myeloma in the context of the bone marrow microenvironment. Front Oncol. 2020;10\u20132020.","DOI":"10.3389\/fonc.2020.608815"},{"issue":"1","key":"3147_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-025-02158-3","volume":"23","author":"M Shi","year":"2025","unstructured":"Shi M, Shen N, Liu X, Yu J, Shen X, Chen Y, et al. Exosome-transmitted HSPA9 facilitates bortezomib resistance by targeting TRIP13\/USP1 signaling in multiple myeloma. Cell Commun Signal. 2025;23(1):152.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"3147_CR24","doi-asserted-by":"publisher","first-page":"14287","DOI":"10.1038\/s41598-020-71138-z","volume":"10","author":"A Tak\u00e1cs","year":"2020","unstructured":"Tak\u00e1cs A, Lajk\u00f3 E, L\u00e1ng O, Istenes I, K\u0151hidai L. Alpha-lipoic acid alters the antitumor effect of bortezomib in melanoma cells in vitro. Sci Rep. 2020;10(1):14287.","journal-title":"Sci Rep"},{"issue":"3","key":"3147_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14030221","volume":"14","author":"AN Kul","year":"2024","unstructured":"Kul AN, Ozturk Kurt B. Multiple myeloma from the perspective of pro-and anti-oxidative parameters: potential for diagnostic and\/or follow-up purposes? J Pers Med. 2024;14(3):221.","journal-title":"J Pers Med"},{"key":"3147_CR26","doi-asserted-by":"publisher","first-page":"1351565","DOI":"10.3389\/fphar.2024.1351565","volume":"15","author":"M Pelon","year":"2024","unstructured":"Pelon M, Krzeminski P, Tracz-Gaszewska Z, Misiewicz-Krzeminska I. Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells. Front Pharmacol. 2024;15:1351565.","journal-title":"Front Pharmacol"},{"issue":"2","key":"3147_CR27","doi-asserted-by":"publisher","first-page":"e0289904","DOI":"10.1371\/journal.pone.0289904","volume":"19","author":"K Zafeiropoulou","year":"2024","unstructured":"Zafeiropoulou K, Kalampounias G, Alexis S, Anastasopoulos D, Symeonidis A, Katsoris P. Autophagy and oxidative stress modulation mediate bortezomib resistance in prostate cancer. PLoS One. 2024;19(2):e0289904.","journal-title":"PLoS One"},{"issue":"6","key":"3147_CR28","doi-asserted-by":"publisher","first-page":"540","DOI":"10.4062\/biomolther.2014.081","volume":"22","author":"HJ Kim","year":"2014","unstructured":"Kim HJ, Park MK, Kim SY, Lee CH. Novel suppressive effects of ketotifen on migration and invasion of MDA-MB-231 and HT-1080 cancer cells. Biomol Ther (Seoul). 2014;22(6):540\u20136.","journal-title":"Biomol Ther (Seoul)"},{"issue":"6","key":"3147_CR29","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1182\/blood-2006-07-027326","volume":"109","author":"CR Isham","year":"2007","unstructured":"Isham CR, Tibodeau JD, Jin W, Xu R, Timm MM, Bible KC. Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. Blood. 2007;109(6):2579\u201388.","journal-title":"Blood"},{"issue":"5","key":"3147_CR30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1046\/j.1365-2184.2000.00191.x","volume":"33","author":"M Molinari","year":"2000","unstructured":"Molinari M. Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif. 2000;33(5):261\u201374.","journal-title":"Cell Prolif"},{"issue":"5\u20136","key":"3147_CR31","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.drudis.2011.12.009","volume":"17","author":"T Chen","year":"2012","unstructured":"Chen T, Stephens PA, Middleton FK, Curtin NJ. Targeting the S and G2 checkpoint to treat cancer. Drug Discov Today. 2012;17(5\u20136):194\u2013202.","journal-title":"Drug Discov Today"},{"issue":"10","key":"3147_CR32","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/S0301-472X(02)00893-7","volume":"30","author":"J Soboloff","year":"2002","unstructured":"Soboloff J, Zhang Y, Minden M, Berger SA. Sensitivity of myeloid leukemia cells to calcium influx blockade: application to bone marrow purging. Exp Hematol. 2002;30(10):1219\u201326.","journal-title":"Exp Hematol"},{"key":"3147_CR33","doi-asserted-by":"publisher","first-page":"692654","DOI":"10.3389\/fimmu.2021.692654","volume":"12","author":"S Hekmatirad","year":"2021","unstructured":"Hekmatirad S, Moloudizargari M, Moghadamnia AA, Kazemi S, Mohammadnia-Afrouzi M, Baeeri M, et al. Inhibition of exosome release sensitizes U937 cells to pegylated liposomal doxorubicin. Front Immunol. 2021;12:692654.","journal-title":"Front Immunol"},{"key":"3147_CR34","first-page":"43","volume":"7","author":"W Pan","year":"2024","unstructured":"Pan W, Miao Q, Yin W, Li X, Ye W, Zhang D, et al. The role and clinical applications of exosomes in cancer drug resistance. Cancer Drug Resist. 2024;7:43.","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"3147_CR35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12865-022-00514-3","volume":"23","author":"Y Peng","year":"2022","unstructured":"Peng Y, Zhao M, Hu Y, Guo H, Zhang Y, Huang Y, et al. Blockade of exosome generation by GW4869 inhibits the education of M2 macrophages in prostate cancer. BMC Immunol. 2022;23(1):37.","journal-title":"BMC Immunol"},{"key":"3147_CR36","doi-asserted-by":"publisher","first-page":"798272","DOI":"10.3389\/fphar.2022.798272","volume":"13","author":"M Bridoux","year":"2022","unstructured":"Bridoux M, Simon N, Turpin A. Proton pump inhibitors and cancer: current state of play. Front Pharmacol. 2022;13:798272.","journal-title":"Front Pharmacol"},{"key":"3147_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23147810","author":"E Rimmer","year":"2022","unstructured":"Rimmer E, Rashid S, Kraev I, Miralles F, Elia A. Extracellular vesicles inhibit the response of pancreatic ductal adenocarcinoma cells to gemcitabine and TRAIL treatment. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23147810.","journal-title":"Int J Mol Sci"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03147-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03147-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03147-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T03:51:04Z","timestamp":1769485864000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03147-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["3147"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03147-9","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"10 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}